Jane Street’s Avalo Therapeutics AVTX Stock Holding History

Jane Street’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07M	Buy	57,800 +37,600	+186%	+$594K	﹤0.01%	6410
2026 Q1	$302K	Buy	+20,200	New	+$316K	﹤0.01%	9228

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jane Street's AVTX Position: Q2 2026 in Review

Jane Street sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 173,320 shares — an estimated $2.74M sold.

Jane Street first reported a position in AVTX in Q2 2020 and held it in 5 quarters. The position peaked at $3.25M in Q4 2025. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Jane Street reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
Jane Street sold 173,320 Avalo Therapeutics shares in Q2 2026, an estimated $2.74M.
Jane Street first reported a position in Avalo Therapeutics in Q2 2020 and held it in 5 quarters.
Jane Street's Avalo Therapeutics position peaked at $3.25M in Q4 2025.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.